Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M
Clinical trial NCT03133546 · COMPLETED
Trial details
- NCT number
- NCT03133546
- Sponsor
- ETOP IBCSG Partners Foundation
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-05-31
- Primary completion
- 2021-02-22
- Enrollment
- 155
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.